Journal Mobile Options
Table of Contents
Vol. 72, Suppl. 1, 2007
Issue release date: December 2007
Section title: Paper
Oncology 2007;72:16–23
(DOI:10.1159/000111703)

Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C

Yu M.-L.a, b, c · Huang C.-F.a, c · Dai C.-Y.a, d, e · Huang J.-F.a, d, f · Chuang W.-L.a, b
aHepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, bHepatobiliary Division, Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, cDepartment of Prevention Medicine, Kaohsiung Medical University Hospital, dGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, eDepartment of Occupational Medicine, Kaohsiung Medical University Hospital, and fDepartment of Internal Medicine, Kaohsiung Municipal Hsiaokang Hospital, Kaohsiung, Taiwan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 12/13/2007
Issue release date: December 2007

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Hepatitis C virus infection frequently causes chronic liver disease leading to cirrhosis and hepatocellular carcinoma (HCC) and has become the main indication for liver transplantation. Interferon (IFN)-based therapy has been used in the treatment of chronic hepatitis C (CHC) for viral clearance. Several earlier studies showed long-term beneficial effects of IFN monotherapy in reducing the progression of cirrhosis, hindering HCC development, and prolonging survival among both sustained virological responders and nonresponders. However, the benefits of preventing disease progression in CHC patients without sustained virological response (SVR) no longer existed over a longer observation period. Both IFN monotherapy and IFN-ribavirin combination therapy were shown to reduce significantly the complications of liver disease, in terms of development of cirrhosis, HCC and liver-related mortality. The significance disappeared after response to antiviral treatment was taken into account. The benefits were obtained mainly from successful antiviral treatment but were not related to the antiviral regimens, suggesting that the magnitude of this preventive effect could increase through the significant improvement of SVR rate by using a more effective regimen, such as interferon-ribavirin or peginterferon-ribavirin combination therapy. Nevertheless, about one-third of patients remain resistant to the current recommended antiviral regimens. More effective treatment is needed for the population.

© 2007 S. Karger AG, Basel


  

Author Contacts

Wan-Long Chuang, MD, PhD
Hepatobiliary Division, Department of Internal Medicine
Kaohsiung Medical University Hospital
No. 100, Tzyou 1st Road, Kaohsiung 807 (Taiwan)
Tel. +886 7 312 1101, ext. 7475, Fax +886 7 323 4553, E-Mail fish6069@gmail.com

  

Article Information

Published online: December 13, 2007
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 1, Number of References : 50

  

Publication Details

Oncology (International Journal of Cancer Research and Treatment)

Vol. 72, No. Suppl. 1, Year 2007 (Cover Date: December 2007)

Journal Editor: Markman, M. (Houston, Tex.)
ISSN: 0030–2414 (print), 1423–0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 12/13/2007
Issue release date: December 2007

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.